Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 10/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PTGER4 | P35408 | 10/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18938868 | 0.88 | PADI4 (0.54) | PADI4PTGER4 | |
| SCHEMBL18247513 | 0.87 | PADI4 (0.51) | PADI4PTGER4 | |
| Lithium SCHEMBL18247699 | 0.86 | PADI4 (0.50) | PADI4PTGER4 | |
| SCHEMBL18247694 | 0.86 | PADI4 (0.50) | PADI4PTGER4 | |
| SCHEMBL18247356 | 0.85 | PADI4 (0.69) | PADI4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18247442 | 0.80 | PADI4 (0.72) | PADI4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25145034 | 0.79 | PADI4 (0.51) | PADI4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18938867 | 0.78 | PADI4 (0.56) | PADI4 | |
| Lithium Ion SCHEMBL18247696 | 0.77 | PADI4 (0.49) | PADI4PDE4APDE4BPDE4CPDE4D | |
| Lithium Ion SCHEMBL30325457 | 0.77 | PADI4 (0.49) | PADI4PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | Jubilant Epipad LLC | 2025-10-02 | — | — | US | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-20200276206-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3684767-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019058393-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | PADI4 1/4885PDE4A 7/4885PDE4B 6/4885 |
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | NES, VHL, ETV6 | PADI4 4577/4885PDE4A 3389/4885PDE4B 3512/4885 |
| US-20200276206-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | PADI4, PADI2, PADI1 | PADI4 1/4885PDE4A 7/4885PDE4B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.